Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years.

U-NET convolutional neural network diffuse large B-cell lymphoma muscle depletion muscle hypodensity sarcopenia

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Sep 2021
Historique:
received: 18 06 2021
revised: 27 08 2021
accepted: 03 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Muscle depletion (MD) assessed by computed tomography (CT) has been shown to be a predictive marker in solid tumors, but has not been assessed in non-Hodgkin's lymphomas. Despite software improvements, MD measurement remains highly time-consuming and cannot be used in clinical practice. This study reports the development of a Deep-Learning automatic segmentation algorithm (DLASA) to measure MD, and investigate its predictive value in a cohort of 656 diffuse large B cell lymphoma (DLBCL) patients included in the GAINED phase III prospective trial (NCT01659099). After training on a series of 190 patients, the DLASA achieved a Dice coefficient of 0.97 ± 0.03. In the cohort, the median skeletal muscle index was 50.2 cm

Sections du résumé

BACKGROUND BACKGROUND
Muscle depletion (MD) assessed by computed tomography (CT) has been shown to be a predictive marker in solid tumors, but has not been assessed in non-Hodgkin's lymphomas. Despite software improvements, MD measurement remains highly time-consuming and cannot be used in clinical practice.
METHODS METHODS
This study reports the development of a Deep-Learning automatic segmentation algorithm (DLASA) to measure MD, and investigate its predictive value in a cohort of 656 diffuse large B cell lymphoma (DLBCL) patients included in the GAINED phase III prospective trial (NCT01659099).
RESULTS RESULTS
After training on a series of 190 patients, the DLASA achieved a Dice coefficient of 0.97 ± 0.03. In the cohort, the median skeletal muscle index was 50.2 cm

Identifiants

pubmed: 34572728
pii: cancers13184503
doi: 10.3390/cancers13184503
pmc: PMC8466314
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01659099']

Types de publication

Journal Article

Langues

eng

Références

Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
Leuk Lymphoma. 2014 Apr;55(4):817-23
pubmed: 23781925
N Engl J Med. 2017 Sep 28;377(13):1250-1260
pubmed: 28953447
Acta Physiol (Oxf). 2014 Mar;210(3):489-97
pubmed: 24393306
Curr Res Transl Med. 2019 Aug;67(3):93-99
pubmed: 30583985
Nutrition. 2019 Mar;59:50-55
pubmed: 30419500
Comput Biol Med. 2017 Aug 1;87:95-103
pubmed: 28558319
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Br J Cancer. 2017 Jan;116(3):310-317
pubmed: 28072766
Eur Radiol. 2018 Jun;28(6):2455-2463
pubmed: 29318425
Front Oncol. 2018 Oct 22;8:457
pubmed: 30460194
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
PLoS One. 2018 Aug 20;13(8):e0202700
pubmed: 30125312
Blood. 2021 Apr 29;137(17):2307-2320
pubmed: 33211799
AMIA Annu Symp Proc. 2018 Apr 16;2017:1140-1148
pubmed: 29854182
Ann Surg Oncol. 2011 Dec;18(13):3579-85
pubmed: 21822551
Phys Med Biol. 2019 Oct 16;64(20):205015
pubmed: 31514173
Acad Radiol. 2020 Mar;27(3):311-320
pubmed: 31126808
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):298-304
pubmed: 27897411
Comput Med Imaging Graph. 2019 Jul;75:47-55
pubmed: 31132616
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 28426181
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Am J Med. 1980 Oct;69(4):491-7
pubmed: 7424938
J Digit Imaging. 2017 Aug;30(4):487-498
pubmed: 28653123
Radiology. 2018 Jul;288(1):177-185
pubmed: 29584598
Proc SPIE Int Soc Opt Eng. 2020 Feb;11317:
pubmed: 32577045
Curr Opin Support Palliat Care. 2009 Dec;3(4):269-75
pubmed: 19667996
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):285-297
pubmed: 27897414
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1362-1370
pubmed: 33097974
Nat Rev Cancer. 2002 Nov;2(11):862-71
pubmed: 12415256
Cancer. 2013 Sep 15;119(18):3377-84
pubmed: 23801109

Auteurs

Maxime Jullien (M)

Department of Hematology, Nantes University Hospital, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, 44000 Nantes, France.

Benoit Tessoulin (B)

Department of Hematology, Nantes University Hospital, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, 44000 Nantes, France.

Hervé Ghesquières (H)

Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Claude Bernard Lyon-1 University, 69310 Pierre Bénite, France.

Lucie Oberic (L)

Department of Hematology, IUC Toulouse Oncopole, 31000 Toulouse, France.

Franck Morschhauser (F)

Department of Hematology, Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, 59000 Lille, France.

Hervé Tilly (H)

Department of Hematology, Centre H. Becquerel, 76000 Rouen, France.

Vincent Ribrag (V)

Department of Hematology, Gustave Roussy, Université Paris-Saclay, 94800 Villejuif, France.

Thierry Lamy (T)

Department of Hematology, University Hospital of Rennes, 35000 Rennes, France.

Catherine Thieblemont (C)

Department of Hematology, APHP, Hopital Saint Louis, Université Paris Diderot, 75011 Paris, France.

Bruno Villemagne (B)

Department of Hematology, Hopital Departemental de Vendée, 85000 La Roche sur Yon, France.

Rémy Gressin (R)

Department of Hematology, CHU Grenoble, 38000 Grenoble, France.

Kamal Bouabdallah (K)

Department of Hematology, University Hospital of Bordeaux, F-33000 Bordeaux, France.

Corinne Haioun (C)

Lymphoïd Malignancies Unit, Hôpital Henri Mondor, AP-HP, 94000 Créteil, France.

Gandhi Damaj (G)

Department of Hematology, Institut D'hématologie de Basse Normandie, 14000 Caen, France.

Luc-Matthieu Fornecker (LM)

Department of Hematology, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospital of Strasbourg, 67000 Strasbourg, France.

Jean-Marc Schiano De Colella (JM)

Department of Hematology, Institut P. Calmette, 13000 Marseille, France.

Pierre Feugier (P)

Department of Hematology, University Hospital of Nancy, 54000 Nancy, France.

Olivier Hermine (O)

Department of Hematology, Hopital Necker, F-75015 Paris, France.

Guillaume Cartron (G)

Department of Clinical Hematology, University Hospital of Montpellier, UMR-CNRS 5535, 34000 Montpellier, France.

Christophe Bonnet (C)

Department of Hematology, CHU Liege, Liege University, 4000 Liege, Belgium.

Marc André (M)

Department of Hematology, CHU UCL Namur, Université Catholique de Louvain, 5000 Namur, Belgium.

Clément Bailly (C)

Department of Nuclear Medicine, University Hospital of Nantes, 44000 Nantes, France.

René-Olivier Casasnovas (RO)

Department of Hematology, University Hospital F. Mitterrand and Inserm UMR 1231, 21000 Dijon, France.

Steven Le Gouill (S)

Department of Hematology, Nantes University Hospital, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, 44000 Nantes, France.

Classifications MeSH